Accepted Manuscript

A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminemia receiving continuous venovenous hemodiafiltration

Fekade B Sime, Janine Stuart, Jenie Butler, Therese Starr, Steven C Wallis, Saurabh Pandey, Jeffrey Lipman, Jason A Roberts

PII: \$0924-8579(18)30199-7

DOI: 10.1016/j.ijantimicag.2018.07.008

Reference: ANTAGE 5489

To appear in: International Journal of Antimicrobial Agents

Received date: 15 May 2018
Revised date: 27 June 2018
Accepted date: 7 July 2018



Please cite this article as: Fekade B Sime, Janine Stuart, Jenie Butler, Therese Starr, Steven C Wallis, Saurabh Pandey, Jeffrey Lipman, Jason A Roberts, A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminemia receiving continuous venovenous hemodiafiltration, *International Journal of Antimicrobial Agents* (2018), doi: 10.1016/j.ijantimicag.2018.07.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Highlights

- Standard IV posaconazole doses may be inadequate for aspergillosis during hypalbuminaemia
- Standard IV posaconazole doses are likely to be adequate for susceptible yeast infections
- No supranormal posaconazole accumulation is anticipated in a patient undergoing CVVHDF

Download English Version:

https://daneshyari.com/en/article/11008466

Download Persian Version:

https://daneshyari.com/article/11008466

<u>Daneshyari.com</u>